JPMorgan analyst Robbie Marcus raised the firm’s price target on Integra LifeSciences (IART) to $13 from $12 and keeps an Underweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences price target lowered to $11 from $12 at Citi
- Integra Lifesciences Faces Revenue Shortfall and Lowered Outlook Amid Supply Chain Challenges
- Integra LifeSciences Reports Strong Q3 2025 Results
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Integra LifeSciences sees Q4 EPS 79c-84c, consensus 92c